|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...8788899091929394959697...39323933» |
- || bleselumab (ASKP1240) / Astellas, Kyowa Kirin
Clinical, P2a data, Journal: Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. (Pubmed Central) - Jul 23, 2024
In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed.
- || Rituxan (rituximab) / Roche
Clinical, Journal: Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. (Pubmed Central) - Jul 23, 2024
However, cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials. Rather, these data should encourage efforts to better understand the disease mechanisms and to search for targeted and less toxic immune modulatory treatment for this patient group.
- | Rituxan (rituximab) / Roche
Journal: Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. (Pubmed Central) - Jul 23, 2024
Value-driven healthcare strategies implemented in Singapore's public healthcare institutions have contributed to high adoption rates of biosimilars and have improved affordable access through lower treatment costs. This in turn has led to significant cost savings to the healthcare system.
- | Rituxan (rituximab) / Roche
Journal: Refractory Immune-Mediated Cysticercal Meningitis and Role of B Cell Depleting Therapy. (Pubmed Central) - Jul 23, 2024
This in turn has led to significant cost savings to the healthcare system. This off-label use of a monoclonal antibody against CD20 may be considered as a rescue therapy in steroid-refractory immune-mediated cysticercal meningitis.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Checkpoint inhibition, Microsatellite instability, PD(L)-1 Biomarker, IO biomarker: Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation. (Pubmed Central) - Jul 23, 2024
Here, we report the case of a patient with pancreatic adenocarcinoma, with confirmed MSI by two independent next-generation sequencing tests, but not by routine methods, who had progression on pembrolizumab. Comparison of the patient's MSI loci patterns with MSI+ colorectal adenocarcinoma samples showed a lower fraction of unstable loci, low resolution of a second peak in the repeat length spectrum of unstable short tandem repeats in the patient's sample, and a lower length of indels (3.7 vs 4.5 base pairs, p
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Checkpoint inhibition: A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma. (Pubmed Central) - Jul 23, 2024
Early recognition of high grade irAEs and prompt intervention is essential. Despite the poor prognosis of these overlap syndromes, current recommendations offer little guidance for severe cases and warrant a call for increased awareness and expansion of available therapeutics.
- | Rituxan (rituximab) / Roche
Journal: ABO-incompatible kidney transplantation using immunoadsorption columns: First experiences in South Africa. (Pubmed Central) - Jul 23, 2024
Despite the poor prognosis of these overlap syndromes, current recommendations offer little guidance for severe cases and warrant a call for increased awareness and expansion of available therapeutics. Glycosorb ABO IA is an effective technique in enabling ABO-incompatible living-donor kidney transplants to be performed successfully in a South African setting.
- | ANV419 / Anaveon
Journal: Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy. (Pubmed Central) - Jul 23, 2024
ANV419 also enhances the NK cell killing capacity and increases tumor growth inhibition when used alongside trastuzumab in a Her-2+ xenograft mouse model...These data support the clinical development of ANV419 in solid tumors and hematological malignancies as monotherapy and in combination with checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. ANV419 is currently in Phase 1/2 clinical development and may provide cancer patients with a wider therapeutic window than aldesleukin.
- ||| Tecentriq (atezolizumab) / Roche, zanzalintinib (XL092) / Exelixis
P3 data, Journal, Metastases: STELLAR-303: randomized phase III study of zanzalintinib (Pubmed Central) - Jul 23, 2024
P3
Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed during/after or are refractory/intolerant to standard-of-care therapy. The primary end point is overall survival in patients without liver metastases.Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov).
- | Ocrevus (ocrelizumab) / Roche
Journal: Ureaplasma urealyticum osteomyelitis of the greater trochanter in a patient with multiple sclerosis using ocrelizumab - a case report. (Pubmed Central) - Jul 23, 2024
A young MS patient developed osteomyelitis from persistent Ureaplasma urealyticum urethritis, which was diagnosed with specialized polymerase chain reaction and resolved with targeted antibiotics. A multidisciplinary approach is crucial for managing such infections.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab. (Pubmed Central) - Jul 23, 2024
A multidisciplinary approach is crucial for managing such infections. No abstract available
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Adverse events, Checkpoint inhibition: Isolated Adrenocorticotropic Hormone (ACTH) Deficiency as an Immune-Related Adverse Event Following Combination Immune Checkpoint Inhibitor Therapy. (Pubmed Central) - Jul 23, 2024
Healthcare providers should maintain a heightened vigilance for eosinophilia and electrolyte imbalances during the administration of ICIs. The detection of even subtle abnormalities in these parameters should prompt immediate consultation with an endocrinologist.
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Retrospective data, Journal, Metastases: Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study. (Pubmed Central) - Jul 23, 2024
However, because observational studies are prone to confounding and selection bias, causality cannot be affirmed. This study did not receive any specific grant.
- | Opdivo (nivolumab) / BMS
Journal, Monotherapy, PD(L)-1 Biomarker, IO biomarker: Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report. (Pubmed Central) - Jul 23, 2024
This patient is still receiving nivolumab with no symptoms and PS 0. Acquired resistance should be judged carefully in patients with LN-only oligo-progression to avoid unnecessary local therapies and the misjudgment of treatment.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Metastases: Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study. (Pubmed Central) - Jul 23, 2024
The findings suggest that the combination of camrelizumab and anlotinib offers a superior anti-tumor response with a manageable safety profile in a second-line setting for ES-SCLC patients. This combination regimen may be a viable option for second-line ES-SCLC treatment.
- || evorpacept (ALX148) / ALX Oncology, magrolimab (ONO-7913) / Ono Pharma
Review, Journal: Targeting the CD47/SIRP? pathway in malignancies: recent progress, difficulties and future perspectives. (Pubmed Central) - Jul 23, 2024
These setbacks have cast doubt on the feasibility of targeting CD47 in the industry. In this review, we delve into the challenges of developing CD47-SIRP?-targeted drugs, analyze factors contributing to the mentioned setbacks, discuss future perspectives, and explore potential solutions for enhancing CD47-SIRP?-targeted drug development.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal: A case report of hemophagocytic lymphohistiocytosis induced by toripalimab plus chemoradiotherapy in cervical cancer. (Pubmed Central) - Jul 23, 2024
Considering the possibility of HLH is needed in patients receiving ICIs to detect rare toxicities at an early stage when the patient develops uncontrollable fever, cytopenia, and splenomegaly, our multidisciplinary treatment modality contributed to the early diagnosis and successful management of HLH, avoiding progressive tissue damage and organ failure. Whether glucocorticoids are used alone or not for immune-associated HLH needs further investigation.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Abrupt progression from patch- to tumor-stage mycosis fungoides following pembrolizumab treatment. (Pubmed Central) - Jul 23, 2024
Whether glucocorticoids are used alone or not for immune-associated HLH needs further investigation. No abstract available
- || Tevimbra (tislelizumab-jsgr) / BeiGene
Review, Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review. (Pubmed Central) - Jul 23, 2024
Each subtype requires different therapeutic approaches, with the PB type primarily treated with gemcitabine and the IN type with 5-FU...According to the latest follow-up, the tumors are effectively controlled. Our utilization of immunotherapy combined with chemotherapy holds significant implication for the treatment of periampullary carcinoma.
- | sunitinib / Generic mfg.
Journal, Tumor cell: CXCL3/TGF-?-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance. (Pubmed Central) - Jul 23, 2024
In turn, transformed NFs promoted the tumor progression and drug resistance of RCC. These findings may constitute potential therapeutic strategies for RCC treatment.
- | Rituxan (rituximab) / Roche
Journal: Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children (Pubmed Central) - Jul 23, 2024
Cerebrospinal fluid and electrophysiological examination are important auxiliary examination methods. If steroid therapy is not effective, plasma exchange and rituximab treatment should be used as soon as possible.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Journal: Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma (Pubmed Central) - Jul 23, 2024
A total of 28 cases of grade 3 or above adverse events were recorded, mainly myelosuppression, all of which were related to chemotherapy and did not affect sequential treatment. Brentuximab vedotin has demonstrated efficacy and a tolerable safety profile in the treatment of refractory and relapsed CD30-positive Hodgkin's lymphoma in children.
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal, Metastases: Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed (Pubmed Central) - Jul 23, 2024
P
To our knowledge, URBAN represents the largest dataset of COVID-19-related outcomes in FL patients extensively exposed to obinutuzumab. ClinicalTrials.gov identifier: NCT04034056.
- | Opdivo (nivolumab) / BMS
Journal, HEOR, Real-world evidence, Real-world: Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 (Pubmed Central) - Jul 23, 2024
ClinicalTrials.gov identifier: NCT04034056. Collectively, our findings suggest that nivolumab 480
- | CD22/CD19 CAR T / The First Affiliated Hospital of Soochow University
Trial primary completion date, CAR T-Cell Therapy: CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL (clinicaltrials.gov) - Jul 23, 2024
P1/2, N=35, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
Collectively, our findings suggest that nivolumab 480 Trial primary completion date: May 2024 --> Dec 2024
- ||||| Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, HEOR, Real-world evidence, Real-world: Observational Study Protocol: LIVER-R (clinicaltrials.gov) - Jul 23, 2024
P=N/A, N=4490, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: May 2024 --> Dec 2024 Initiation date: Dec 2023 --> Jan 2023
- || DKY709 / Novartis, spartalizumab (PDR001) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - Jul 23, 2024
P1, N=98, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2023 --> Jan 2023 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- | Opdivo (nivolumab) / BMS
Enrollment open, Checkpoint inhibition: Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies (clinicaltrials.gov) - Jul 23, 2024
P1, N=10, Recruiting, Sponsor: David Ilan Sandberg
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- | TTRNA-DC vaccines with GM-CSF and TTRNA-xALT / University of Florida
New P1 trial, Checkpoint inhibition, Checkpoint block: MATCHPOINT: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma (clinicaltrials.gov) - Jul 23, 2024
P1, N=12, Not yet recruiting, Sponsor: University of Florida
- ||| Stivarga (regorafenib) / Bayer
Trial completion, Combination therapy, Metastases: A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors (clinicaltrials.gov) - Jul 23, 2024
P2, N=175, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Enrollment closed, Enrollment change: Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) (clinicaltrials.gov) - Jul 23, 2024
P1/2, N=45, Active, not recruiting, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=15 --> 45
- | Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma (clinicaltrials.gov) - Jul 23, 2024
P3, N=23, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | N=15 --> 45 Trial primary completion date: Jun 2024 --> Mar 2027
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas (clinicaltrials.gov) - Jul 23, 2024
P1, N=6, Recruiting, Sponsor: West China Hospital
Trial primary completion date: Jun 2024 --> Mar 2027 N=12 --> 6
- ||| Opdivo (nivolumab) / BMS
Trial completion date: CheckMate 77T: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer (clinicaltrials.gov) - Jul 23, 2024
P3, N=461, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=12 --> 6 Trial completion date: Sep 2024 --> Jul 2027
- ||| Imfinzi (durvalumab) / AstraZeneca, Orpathys (savolitinib) / AstraZeneca, Hutchmed
Trial completion date, Monotherapy, Metastases: SAMETA: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC (clinicaltrials.gov) - Jul 23, 2024
P3, N=220, Recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2024 --> Jul 2027 Trial completion date: Sep 2026 --> Jun 2026
- | Verzenio (abemaciclib) / Eli Lilly
Trial initiation date, Combination therapy, Monotherapy: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy (clinicaltrials.gov) - Jul 23, 2024
P2, N=45, Not yet recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Sep 2026 --> Jun 2026 Initiation date: Jun 2024 --> Sep 2024
- tizaterkib (ATG-017) / Antengene
Enrollment change, Trial termination, Combination therapy, Monotherapy, Metastases: ERASER: Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (clinicaltrials.gov) - Jul 23, 2024
P1, N=36, Terminated, Sponsor: Antengene Therapeutics Limited
Initiation date: Jun 2024 --> Sep 2024 N=211 --> 36 | Recruiting --> Terminated; The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio.
- | PNV21 vaccine / Fred Hutchinson Cancer Center
Trial completion date, Trial primary completion date, Metastases: Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer (clinicaltrials.gov) - Jul 23, 2024
P1, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Center
N=211 --> 36 | Recruiting --> Terminated; The study was terminated based on the internal need to re-prioritization the whole pipeline and phase 1 portfolio. Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
- | BI 765063 / Boehringer Ingelheim, BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Metastases: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer (clinicaltrials.gov) - Jul 22, 2024
P1, N=48, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025 Trial primary completion date: Nov 2024 --> Jul 2024
- || Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment open, Combination therapy: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Jul 22, 2024
P1/2, N=40, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Nov 2024 --> Jul 2024 Not yet recruiting --> Recruiting
- |||| WU CART 007 / Wugen
New P2 trial, CAR T-Cell Therapy, Minimal residual disease: A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy inT-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (clinicaltrials.gov) - Jul 22, 2024
P2, N=125, Not yet recruiting, Sponsor: Wugen, Inc.
- | tomivosertib (eFT508) / eFFECTOR Therap
Preclinical, Journal: ephrin-B2 promotes nociceptive plasticity and hyperalgesic priming through EphB2-MNK-eIF4E signaling in both mice and humans. (Pubmed Central) - Jul 22, 2024
In experiments on human DRG neurons, ephrin-B2 increased eIF4E phosphorylation and enhanced Ca2+ responses to PGE2 treatment, both blocked by eFT508. We conclude that ephrin-B2 acts directly on mouse and human sensory neurons to induce nociceptor plasticity via MNK-eIF4E signaling, offering new insight into how ephrin-B signaling promotes pain.
- | Enrollment closed, Trial completion date, Trial primary completion date, Metastases: First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - Jul 22, 2024
P2, N=32, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
We conclude that ephrin-B2 acts directly on mouse and human sensory neurons to induce nociceptor plasticity via MNK-eIF4E signaling, offering new insight into how ephrin-B signaling promotes pain. Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027
- | Breyanzi (lisocabtagene maraleucel) / BMS, Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead
Reimbursement, US reimbursement, Journal, CAR T-Cell Therapy, Medicare: Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Jul 22, 2024
This study helps understand providers' cost and associated patient care around CAR T administration. The data show that the average cost received by hospitals encompasses the expenses related to both the CAR T drug and the medical services delivered to patients.
- | Vumerity (diroximel fumarate) / Biogen, Ocrevus (ocrelizumab) / Roche
Journal: De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate. (Pubmed Central) - Jul 22, 2024
These preliminary findings suggest that transition to DRF from OCRE may be an effective treatment option for people with RRMS who are clinically stable but may need to switch for reasons unrelated to effectiveness. Longer follow-up times on larger samples are needed to confirm these observations.
- | Opdivo (nivolumab) / BMS
Journal, Microsatellite instability, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer. (Pubmed Central) - Jul 22, 2024
P1b/2
Three-year outcomes of patients with MSI-H were better than those of patients with MSS. PD-L1 positivity, elevated CD8/eTreg ratio, and high expression of Ki-67, CTLA-4, and PD-1 could be positive predictors of prognosis in patients with MSS.
- | Ibrance (palbociclib) / Pfizer
Journal: DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity. (Pubmed Central) - Jul 22, 2024
PD-L1 positivity, elevated CD8/eTreg ratio, and high expression of Ki-67, CTLA-4, and PD-1 could be positive predictors of prognosis in patients with MSS. Our work uncovers a novel function of DYNLL1 in orchestrating cell cycle to promote HCC development and suggests a potential synergy of CDK4/6 inhibitor and sorafenib for the treatment of HCC patients, especially those with increased DYNLL1.
- | sunitinib / Generic mfg.
Journal: PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-? pathway. (Pubmed Central) - Jul 22, 2024
Our findings establish the miR-15b/PDZK1/PDGFR-? axis as a promising therapeutic target and a novel predictor for ccRCC patients' response to sunitinib treatment.
- || Ocrevus (ocrelizumab) / Roche
Review, Journal: An Unusual Case of Cutaneous Sarcoidosis Following Treatment with Ocrelizumab: Case Report and Literature Review. (Pubmed Central) - Jul 22, 2024
axis as a promising therapeutic target and a novel predictor for ccRCC patients' response to sunitinib treatment. No abstract available
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Journal: Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis. (Pubmed Central) - Jul 22, 2024
Our findings did not confirm a preventive role of early initiation of immunosuppressive therapy vs late initiation on ILD development. However, our findings should be interpreted with caution, considering the high inflammatory, ATA-positive enriched nature of the cohort, confounding by indication, and very few patients were treated with biologicals.